Phase Space Research

PTC Inc

PTC · Investment summary · as of 30 July 2026

Priced close to what the business has demonstrated

Portfolio decision
Pending strategy review
Price · 30 July 2026
$136.29
12-month target
$132.59 -3%
Expected return
-2.7%
Next decision point
Date not announced

Business type: Compounder · mature and structurally stable

Investment view

At $136.29, PTC requires a 6% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 9%.

The value rests on an exit multiple of 15.1x and a terminal operating margin of 34%. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.

The strongest argument against this view: Cause: the ASC 606 cohort that inflated FY2025 does not repeat, and FY2027 laps it.

Underwriting bridge

QuestionEvidence-based conclusion
What drives the business?Not determined — the operating driver is not stated in one place
What do we forecast?Revenue growth of 9% demonstrated; a terminal operating margin of 34%; an exit multiple of 15.1x.
What does Street forecast?Not determined — no consensus estimates are joined to this record
Where do we differ?On revenue growth, the difference between what the price requires and what the business has demonstrated is +3.6 percentage points.
What is it worth?Twelve-month target $132.59, -3% from the struck price. Scenario-weighted expected return net of costs -2.7%.
Why now?Date not announced — no dated event that would resolve the disagreement is on file

What must go right

Not determined — no falsifiable operating conditions are on file for this name, so the thesis cannot be reduced to a small number of testable claims

Catalysts and falsifiers

Date not announced — no dated event that would resolve the disagreement is on file

Risk and sell discipline

Impairment case

Cause: the ASC 606 cohort that inflated FY2025 does not repeat, and FY2027 laps it. FY2025 revenue grew 19% and operating margin +1030bp on "higher total value and longer average duration of contracts that commenced in the current year." Long-duration contracts recognised upfront do not recur until they renew. FY2026 is already guiding revenue −2% to 0% against that base. If FY2027 contract duration mean-reverts further while ARR compounds at 9%, reported revenue can fall again even as the business grows — and the market, which prices PTC on a 15.05x trailing EV/EBIT that was built on a $1,117

Fundamental invalidation

Not determined — no falsifiable invalidation conditions are on file, so this position cannot be risk-monitored

Price-based risk trigger

A daily close below $119.94 triggers an immediate review of the thesis and pauses additional buying. It is not an automatic sell unless a separate fundamental invalidation condition has been breached.

Upside sell discipline

On approach to the $132.59 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.

Investment criteria

CriteriaStatusInvestment meaning
QualityMetIs the business worth owning under its declared economic type?
ValuationMetIs the operating path required by today's price achievable?
LiquidityNot determinedCan the intended position be built and exited in the right vehicle? Not established on the evidence on file.
DownsideMetCause: the ASC 606 cohort that inflated FY2025 does not repeat, and FY2027 laps it.
MomentumNot determinedDoes price action support or complicate entry timing? Not established on the evidence on file.
CatalystNot determinedIs there a dated event that resolves the disagreement? Not established on the evidence on file.
ConsensusNot determinedIs the house-versus-Street disagreement identified and quantified? Not established on the evidence on file.

Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.

Bottom line

The strongest case for mispricing is that the business already delivers +3.6 percentage points more growth than the price requires. The most important unresolved uncertainty is whether a position could be built and exited at the intended size. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $119.94, which forces an immediate review.